Trial · NCT07903415
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Adverse Events (AEs) | Start of study treatment to 30 days after the last dose of study drug administration or start of new anticancer therapy (whichever occurs first) | Number of participants with AEs, characterized by type, frequency, severity, seriousness, and relationship to study intervention during the AE evaluation period. |
| Primary | Part 1: Recommended Monotherapy Dose(s) for Expansion (RDEM) | From first dose through completion of Part 1, an average of 1 year | |
| Primary | Part 2: Recommended Monotherapy Dose for Further Development | From first dose through completion of Part 2, an average of 2 years | |
| Secondary | Objective Response Rate (ORR) | From baseline until first documented disease progression, death, or start of new anticancer therapy, whichever occurs first, up to approximately 3 years | Percentage of participants with a confirmed complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by the investigator. |
| Secondary | Duration of Response (DOR) | From the date of first objective response until disease progression or death due to any cause, whichever occurs first, up to approximately 3 years | Time in weeks/months from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. |
| Secondary | Progression Free Survival (PFS) | From first dose until disease progression or death due to any cause, whichever occurs first, up to approximately 3 years | PFS as defined per RECIST 1.1. |
| Secondary | Overall Survival (OS) | From first dose until death due to any cause, up to approximately 3 years | Time in weeks from the start of study treatment to date of death due to any cause. |
| Secondary | Maximum Observed Serum Concentration (Cmax) | From first dose through End of Treatment (EOT), up to approximately 3 years | |
| Secondary | Area under the concentration-time curve (AUC) | From first dose through End of Treatment (EOT), up to approximately 3 years | |
| Secondary | Time to Maximum Observed Serum Concentration (Tmax) | From first dose through End of Treatment (EOT), up to approximately 3 years | |
| Secondary | Number of Participants With Anti-drug Antibody (ADA) against PF-08098488 | Start of study treatment to 30 days after last dose of study drug administration |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07903415/registered